What Is PT-141?
PT-141 is the research name for:
Bremelanotide
It is a synthetic cyclic peptide related to the body’s melanocortin system.
Its scientific history is closely tied to Melanotan II.
During early Melanotan II research, investigators noticed unexpected sexual effects—including erections and increased sexual desire.
Researchers then developed PT-141 to preserve those sexual-response effects without focusing on the pigmentation effects that made Melanotan II famous.
That development eventually produced something relatively unusual in our library:
An FDA-approved peptide medication.
Bremelanotide is marketed in the United States as:
Vyleesi
and is FDA approved for a specific form of low sexual desire in certain premenopausal women.
Is PT-141 the Same as Bremelanotide?
Essentially, yes.
PT-141 was the developmental/research name.
Bremelanotide is the drug’s generic name.
Vyleesi is the FDA-approved brand.
However, there is an important product-quality distinction.
A vial sold online as “PT-141 research peptide” is not automatically equivalent to pharmaceutical Vyleesi.
FDA-approved Vyleesi has:
standardized manufacturing + controlled formulation + clinical trial evidence + approved labeling + regulated distribution.
Those assurances don’t automatically apply to research-market products.
Where Did PT-141 Come From?
Its story starts with:
α-MSH → Melanotan II → PT-141/Bremelanotide.
Alpha-melanocyte-stimulating hormone, or α-MSH, communicates with a family of receptors called:
melanocortin receptors.
Researchers originally developed Melanotan compounds primarily because of their effects on pigmentation.
But Melanotan II unexpectedly caused sexual responses in human experiments.
That prompted development of bremelanotide as a compound specifically aimed at the central nervous system pathways involved in sexual response.
So PT-141 wasn’t discovered because scientists started with an aphrodisiac.
It grew out of an unexpected observation during pigmentation research.
How Does PT-141 Work?
Bremelanotide is a melanocortin receptor agonist.
It activates melanocortin receptors, with its sexual effects believed to involve primarily central nervous system pathways.
That’s what makes PT-141 quite different from medications such as sildenafil.
Instead of primarily affecting blood vessels in genital tissue, bremelanotide acts more upstream in the brain’s sexual-response circuitry. Reviews of the melanocortin system describe bremelanotide as a centrally acting compound affecting sexual motivation and response.
In simplified terms:
brain signaling → melanocortin receptors → sexual motivation/arousal pathways
rather than simply:
blood vessel dilation → erection.
What Is HSDD?
HSDD stands for:
Hypoactive Sexual Desire Disorder
It refers to persistently low sexual desire that causes meaningful personal distress.
The FDA-approved indication for Vyleesi is much narrower than simply:
“low libido.”
Vyleesi is indicated for premenopausal women with acquired, generalized HSDD when the low sexual desire isn’t due to another medical or psychiatric condition, relationship problems, or medication/drug effects.
Breaking that down:
Acquired means the problem developed after previously normal sexual desire.
Generalized means it isn’t limited to one partner, situation, or type of sexual activity.
And importantly:
Vyleesi is not FDA approved simply to enhance sexual performance.
FDA’s labeling says exactly that.
Does Bremelanotide Actually Improve Female Sexual Desire?
There is real Phase 3 human evidence.
Two large randomized, double-blind, placebo-controlled Phase 3 trials known as the RECONNECT studies enrolled 1,267 premenopausal women with HSDD.
Compared with placebo, bremelanotide produced statistically significant improvements in:
sexual desire
and:
distress related to low sexual desire.
That’s the clinical evidence that ultimately supported approval.
So unlike many experimental peptides:
PT-141 has demonstrated human efficacy in controlled Phase 3 trials.
How Big Was the Benefit?
This deserves some nuance.
The Phase 3 trials found statistically significant improvements in the primary measures of desire and distress.
But critics have questioned the clinical significance of those improvements and the validity/reporting of some trial outcome measures. Later analyses argued that the overall effect size was relatively modest and raised concerns about how several outcomes were selected and reported.
So both statements can be true:
Bremelanotide beat placebo on the FDA-supporting primary endpoints.
And:
The average benefit was not enormous, and researchers continue to debate how clinically meaningful some of the measured changes were.
That’s much more useful than calling it either a miracle libido drug or saying it doesn’t work.
Does PT-141 Increase Libido?
In some people, yes.
Its approved use specifically involves low sexual desire.
Clinical research supports an effect on sexual desire, not merely genital blood flow.
That’s one of the features that makes it unusual among sexual-health medications.
PT-141 is therefore frequently discussed around:
- Low libido
- Sexual motivation
- Reduced sexual interest
- Sexual arousal
- Sexual distress
But the approved indication remains much more specific than all forms of low libido.
Someone whose reduced sexual desire comes primarily from:
relationship stress + depression + medication side effects + hormonal disorders + pain + menopause
doesn’t automatically have the condition Vyleesi was approved to treat.
What About Female Arousal?
Desire and arousal overlap but aren’t identical.
Bremelanotide’s melanocortin activity may influence central sexual excitation and motivation, which can affect several aspects of sexual response.
The Phase 3 development program focused primarily on desire and distress, rather than establishing PT-141 as a universal treatment for all female arousal disorders.
So saying:
“PT-141 increases female sexual desire in appropriately selected patients”
is supported.
Saying:
“PT-141 fixes every form of female sexual dysfunction”
is not.
What About Men?
Here’s where PT-141 gets especially interesting.
Before its FDA approval in women, bremelanotide was extensively investigated in men with erectile dysfunction.
Early controlled studies showed that intranasal PT-141 could produce erections in both healthy men and men with mild-to-moderate ED.
One double-blind placebo-controlled study found significantly greater erectile responses at certain doses, with the first erection occurring at roughly 30 minutes in responding participants.
So the male sexual-response research is absolutely real.
What About Men Who Didn’t Respond to Viagra?
This was studied too.
A randomized double-blind placebo-controlled study included 342 men with erectile dysfunction who had not responded to sildenafil.
The researchers reported positive clinical results in about 33.5% of men receiving bremelanotide versus 8.5% receiving placebo, along with improved intercourse satisfaction.
That’s a legitimate and fairly sizable human trial.
But:
Bremelanotide still isn’t FDA approved for erectile dysfunction in men.
Even in 2026, researchers continue discussing whether bremelanotide should be explored further for male sexual desire and arousal disorders.
So male use remains an area with human evidence but without an FDA-approved indication.
PT-141 vs. Viagra
These compounds work very differently.
Sildenafil / Viagra
Primarily works through:
PDE5 inhibition → nitric oxide signaling → increased genital blood flow.
It helps the physical erectile mechanism.
PT-141 / Bremelanotide
Primarily acts through:
melanocortin receptors → central nervous system sexual-response pathways.
That’s why researchers became interested in PT-141 for men who didn’t respond adequately to sildenafil.
In simplified terms:
Viagra works mostly downstream on blood flow.
PT-141 works more centrally on the brain’s sexual-response circuitry.
Neither mechanism means one is automatically better than the other.
PT-141 vs. Melanotan II
This connection matters because people frequently confuse them.
Melanotan II
Has effects involving:
pigmentation + sexual response + appetite + broader melanocortin activity.
PT-141 / Bremelanotide
Was developed from Melanotan-related research with greater emphasis on:
sexual response rather than tanning.
Bremelanotide can still produce pigmentation-related effects, however.
That’s because it remains a melanocortin agonist.
Can PT-141 Darken the Skin?
Yes.
FDA labeling includes a warning for focal hyperpigmentation.
Darkening has been reported in areas including:
- Face
- Gums
- Breasts
In Phase 3 trials using intermittent dosing, focal hyperpigmentation occurred in about 1% of treated participants.
In another study involving much more frequent daily use, the rate was dramatically higher. FDA also notes that pigmentation changes may not completely disappear after stopping treatment.
That’s an important reminder that PT-141 still belongs to the melanocortin family.
Removing “tanning” from the marketing doesn’t remove the underlying biology.
What About Nausea?
This is probably the most important common side effect.
In the Phase 3 trials:
About 40% of Vyleesi-treated participants experienced nausea.
Around 13% required anti-nausea treatment, and nausea caused roughly 8% of participants to discontinue treatment.
Other common effects included:
- Flushing
- Headache
- Injection-site reactions
The Phase 3 publication similarly reported nausea, flushing, and headache more frequently with bremelanotide than placebo.
So yes, the sexual-response effect is real.
But the nausea reputation is also very real.
What About Blood Pressure?
Bremelanotide can temporarily increase blood pressure and decrease heart rate.
FDA reports average maximum increases of approximately:
6 mmHg systolic
and:
3 mmHg diastolic
with effects peaking about 2–4 hours after administration and generally returning to baseline within 12 hours.
Because of this:
Vyleesi is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.
FDA also recommends evaluating cardiovascular risk before use.
This is an especially important counterweight to research-market descriptions portraying PT-141 as a harmless “libido peptide.”
It is a pharmacologically active prescription drug.
What About Heart Rate?
Interestingly, blood pressure may go up while heart rate temporarily goes down.
FDA observed reductions of up to approximately 5 beats per minute after administration in clinical studies.
These cardiovascular effects usually resolve, but they’re why the medication isn’t appropriate for everyone.
Does PT-141 Affect Hormones?
PT-141 isn’t simply replacement estrogen, testosterone, or another sex hormone.
Its primary activity involves the melanocortin nervous-system pathway.
That’s part of what makes it unusual.
A person can theoretically have adequate sex-hormone levels but still experience problems involving:
sexual motivation + neural processing of erotic cues + central sexual excitation/inhibition.
Bremelanotide targets that central signaling system rather than directly replacing sex hormones.
What About Menopause?
The current FDA indication is specifically for:
premenopausal women.
FDA labeling states Vyleesi is not indicated for treatment of HSDD in postmenopausal women.
That doesn’t mean scientists can never study bremelanotide after menopause.
It means the current approval does not extend to that population.
What About SSRI Sexual Dysfunction?
This is another common search.
Antidepressants—particularly SSRIs—can reduce:
- Libido
- Arousal
- Orgasm
- Sexual responsiveness
Because bremelanotide acts through central sexual-response pathways, it’s understandable why researchers and patients might wonder about SSRI-related sexual dysfunction.
But Vyleesi’s approved HSDD indication specifically excludes low desire attributable primarily to medication effects.
So PT-141 shouldn’t be described as an established treatment for SSRI-induced sexual dysfunction.
What About Testosterone & PT-141 Together?
These often get discussed in peptide and hormone communities.
They address very different systems.
Testosterone: sex steroid hormone.
PT-141: melanocortin receptor agonist.
There’s no strong evidence establishing that combining them produces a special synergistic sexual effect.
Someone’s underlying cause of low desire matters much more than simply stacking compounds with different mechanisms.
Evidence Snapshot
Melanocortin Biology: Strong
Human Research: Yes
Large Phase 3 Trials: Yes
Female HSDD Evidence: Yes
FDA Approval: Yes — as Vyleesi for specific premenopausal women with acquired, generalized HSDD
Male Erectile-Dysfunction Research: Yes
Male FDA Approval: No
Libido/Desire Effects: Human evidence exists
Nausea Risk: Well established
Temporary Blood-Pressure Increase: Well established
Hyperpigmentation Risk: Established
Long-Term Recreational PT-141 Evidence: Limited
This is one of the better-supported compounds in our library because it has gone through actual pharmaceutical development and Phase 3 trials.
What Do We Know?
Bremelanotide genuinely affects human sexual-response biology.
Phase 3 trials demonstrated improvements in sexual desire and distress related to low desire in premenopausal women with HSDD.
Earlier controlled studies also demonstrated erectile responses in men, including some who didn’t respond adequately to sildenafil.
We also have reasonably well-characterized short-term safety information from the approved pharmaceutical product.
That’s considerably more evidence than exists for most research-market peptides.
What Don’t We Know?
We don’t have strong evidence establishing PT-141 as a treatment for:
- Every form of low libido
- Postmenopausal low desire
- Relationship-related loss of desire
- Depression-related low libido
- SSRI-induced sexual dysfunction
- Low testosterone
- Erectile dysfunction as an FDA-approved indication
- Male low-libido disorders generally
- Infertility
- Orgasm disorders broadly
- Long-term daily sexual enhancement
- General sexual performance enhancement
And the safety/effectiveness of unregulated research-market PT-141 products cannot be assumed from pharmaceutical Vyleesi data.
What About Safety?
This is not a biologically mild compound just because it’s called a peptide.
FDA-approved bremelanotide can cause:
nausea + flushing + headache + temporary blood-pressure elevation + heart-rate reduction + focal hyperpigmentation.
It is contraindicated in:
uncontrolled hypertension
and:
known cardiovascular disease.
Research-market products introduce additional uncertainty involving:
- Actual identity
- Concentration
- Purity
- Sterility
- Contamination
- Manufacturing consistency
Those concerns are separate from the known pharmacologic risks of bremelanotide itself.
Research & Regulatory Status
Bremelanotide is unusual because:
It IS FDA approved.
The FDA-approved product is Vyleesi, a bremelanotide injection for acquired, generalized HSDD in premenopausal women under the criteria described in the labeling.
It is not FDA approved:
- For men
- For erectile dysfunction
- For postmenopausal women
- For cosmetic sexual enhancement
- Simply to increase sexual performance
FDA explicitly states Vyleesi is not intended to enhance sexual performance.
That distinction should remain crystal clear on an educational peptide site.
Your Pep Resource Takeaway
PT-141 is one of the best examples of peptide research actually becoming medicine.
Its history is wild:
Melanotan research → unexpected sexual effects → development of PT-141 → controlled trials → Phase 3 HSDD research → FDA-approved bremelanotide.
And the biology is genuinely different from drugs like Viagra.
Instead of primarily manipulating genital blood flow, PT-141 targets brain melanocortin pathways involved in sexual motivation and response.
The human evidence isn’t limited to women either. Controlled studies showed meaningful erectile responses in some men, including sildenafil nonresponders.
But that shouldn’t get turned into:
“PT-141 is a universal libido peptide for men and women.”
Vyleesi’s proven and approved use is much narrower.
Its effects are also strong enough to cause real adverse reactions—especially nausea, temporary blood-pressure increases, and pigmentation changes.
So PT-141 is not internet peptide mythology.
It’s real pharmacology.
And that’s exactly why its benefits, limitations, and risks deserve to be described accurately.
Research Areas / Search Keywords
PT-141, PT141, PT 141, bremelanotide, bremelanotide peptide, Vyleesi, Vyleesi injection, libido peptide, libido, low libido, low sex drive, sex drive, decreased sex drive, sexual desire, sexual desire research, sexual arousal, sexual arousal research, sexual motivation, sexual interest, sexual response, female libido, women’s libido, women’s sexual health, female sexual dysfunction, FSD, hypoactive sexual desire disorder, HSDD, acquired HSDD, generalized HSDD, low desire disorder, sexual distress, loss of sexual desire, premenopausal women, premenopausal sexual health, female arousal research, postmenopausal libido research, menopause libido research, men’s libido, male libido research, male sexual health, erectile dysfunction research, ED research, erections, erectile response, erection peptide, sildenafil nonresponder, Viagra nonresponder, Viagra alternative research, sildenafil, Viagra, PDE5 inhibitor comparison, PT-141 vs Viagra, PT-141 vs Cialis, tadalafil research, central sexual response, brain sexual response, sexual brain pathways, melanocortin, melanocortin system, melanocortin receptor, melanocortin agonist, MC3R, MC4R, alpha-MSH, α-MSH, melanocyte stimulating hormone, Melanotan II, Melanotan 2, MT-2, MT2, PT-141 vs Melanotan II, bremelanotide vs Melanotan, female sexual interest, sexual performance research, orgasm research, orgasm difficulty research, sexual satisfaction, sexual dysfunction, antidepressant sexual dysfunction research, SSRI sexual dysfunction, SSRI low libido, testosterone research, hormones and libido, estrogen and libido, low testosterone research, sexual medicine, sexual wellness research, nausea, PT-141 nausea, flushing, headache, blood pressure, temporary high blood pressure, hypertension, cardiovascular risk, heart rate, hyperpigmentation, skin darkening, gum darkening, breast pigmentation, melanocortin pigmentation, FDA approved peptide, FDA approved libido medication, Vyleesi HSDD, research peptides.
Educational Disclaimer: This profile is provided for educational and research-information purposes only. It is not medical advice and does not provide dosing, administration, sexual-health treatment, or purchasing recommendations. Bremelanotide is FDA approved as Vyleesi for acquired, generalized HSDD in certain premenopausal women. That approval does not extend to men, erectile dysfunction, postmenopausal women, or general sexual-performance enhancement, and it does not establish the quality or safety of research-market PT-141 products.